ABSTRACT Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taldng hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase
Antibodies directed against a variety ofnuclear components are produced by individuals with systemic lupus erythematosus (SLE) and other rheumatic autoimmune diseases. These antinuclear antibodies (ANA) include those directed against DNA (1, 2), RNA (3) , histones (4), nucleolar components (5), poly(ADPribose) (6) , and antigens found in soluble nuclear extracts, commonly referred to as extractable nuclear antigens (ENA) (7) (8) (9) (10) (11) (12) (13) . Antibodies against at least two of the ENA, designated RNP (ribonucleoprotein) and SS-B (Sj6gren syndrome antigen system B), apparently correlate with certain clinical features of connective tissue diseases (9) (10) (11) . Although the molecular identities of some of the nuclear antigens are known (e.g., DNA, RNA, histones), the majority are defined only by their immunological and physicochemical characteristics. The identification of these antigens as proteins with specific cellular functions could lead to the elucidation of the etiologies of the autoimmune diseases.
RNA polymerases, the enzymes catalyzing the transcription of DNA into RNA, would be expected to be among the many proteins present in the nuclear extracts used as the source of ENA. The structure and regulation of RNA polymerases has been a major interest in this laboratory (14) (15) (16) (17) . The observation that sera from some individuals with rheumatic disease contain antibodies against nucleolar components (5) prompted us to investigate whether antibodies directed against RNA polymerase I, an enzyme of nucleolar origin (15) , were present in the sera of these individuals. We now report that sera from patients with SLE, mixed connective tissue disease (MCTD), and rheumatoid arthritis (RA) contain anti-RNA polymerase I antibodies.
METHODS
Solid-Phase Radioimmunoassay (RBA). RNA polymerase I, purified (14, 18) from isolated nuclei ofa rat tumor (Morris hepatoma 3924A), was diluted with buffer A [25 mM potassium phosphate, pH 7.5/150 mM NaCl/0.01% (wt/vol) NaN3] so that the final concentration of protein was 20 A.g/ml. Diluted enzyme (100 A.l) was placed into 400-A.l capacity, flat-bottom wells (Removawell strips; Dynatech, Alexandria, VA). After incubation at 370C for 5 hr in a humidified chamber with gentle shaking, the solution was removed and the wells were washed with buffer A (four washes of 100 p1 each). Buffer A (150 ul), containing 1% (wt/vol) bovine serum albumin then was placed into each well and incubated for 1 hr at room temperature on a rocking platform. After removal of the albumin-containing buffer, 100 A.l of human or rabbit serum diluted 1:10 with buffer B [50 mM Tris HCl, pH 7.4/150 mM NaCl/5 mM EDTA/ 0.05% (wt/vol) Nonidet P40/0.1 mM phenylmethylsulfonyl fluoride] was added and the wells were incubated for 1 hr at room temperature and for 16 hr at 40C. The sera were removed, the wells were washed with buffer B (four washes of 100 dul each), and l"I-labeled protein A [Staphylococcus aureus ; 30 ,ACi/Aug; 1 Ci = 3.7 X 1010 becquerels (125I-protein A)] in buffer B was added to each well (100 1.d per well; 0.01 ,uCi per well).
After incubation for 2 hr at room temperature, the 125I-protein A solution was removed and the wells were washed four times with 100 A.l (each time) of buffer C [50 mM Tris HCl, pH 7.4/ 1.0 M NaCl/5 mM EDTA/0.4% (wt/vol) N-lauroylsarcosine/ 0.1 mM phenylmethylsulfonyl fluoride]. Bound 125I-protein A was then quantitated in a gamma counter. Wells prepared in the absence of enzyme served as controls. In some instances, rat hepatoma poly(A) polymerase, purified as described (19, 20) , was adsorbed to the wells in place of RNA polymerase I as an additional control. Antisera produced by rabbits immunized with RNA polymerase I (17) efficiently bound to the immobiAbbreviations: SLE, systemic lupus erythematosus; ANA, antinuclear antibody(ies); ENA, extractable nuclear antigens; MCTD, mixed connective tissue disease; RA, rheumatoid arthritis; RNP, ribonucleoprotein; RIA, radioimmunoassay; DBM, diazobenzyloxymethyl.
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RESULTS
Anti-RNA Polymerase IAntibodies in Human Sera. Samples of sera from several healthy persons, from patients with rheumatic autoimmune diseases, and from hypertensive individuals receiving medication known to induce a lupus-related state (24) were tested for the presence ofantibodies to rat hepatoma RNA polymerase I by using a solid-phase RIA (Fig. 1 ). Significant (P < 0.01 in a Student's t test) levels of anti-RNA polymerase I antibodies were detected in the sera of all patients with SLE (A) or MCTD (B) and in the sera of 78% of the RA patients (C), when compared with samples from healthy persons (E). As a group, individuals diagnosed as having MCTD had the highest relative concentration of these antibodies in their sera (mean corrected cpm from Fig. 1 (17, 27) . The filters were incubated with sera from rabbits that had been immunized with RNA polymerase I (A) or poly(A) polymerase (B) or with sera from SLE patients S.S., D.S., and A.F. (C, D, and E, respectively) or MCTD patients I.S., C.C., M.B., and S.B. (F, G, H, and I, respectively). Immune complexes were detected by incubating the filters with '251-protein A; this was followed by autoradiography (28 (Fig. 1) (Fig. 2 C-E Purified rat hepatoma RNA polymerase 1 (200 pg) was subjected to polyacrylamide gel electrophoresis under denaturing conditions (17) . The gel track (1.0 x 7.5 cm) was sliced, and each slice (1.0 x 0.2 cm) was homogenized and incubated in 1.5 ml of buffer A for 16 hr at 40C. The homogenized gel slices then were removed by centrifugation and the supernatant fractions, containing RNA polymerase I polypeptides, were used as the antigens in the solid-phase RIA (see Methods). Results are the mean of the duplicate determinations. * Serum from a rabbit that had been immunized with RNA polymerase I was used to determine which gel slices contained polymerase polypeptides. These results were confirmed by staining a parallel gel track that contained the enzyme with Coomassie blue R-250.
phase RIA and DBM-filters may have been due to differential transfer of the polypeptides from polyacrylamide gels to the DBM-filters and to denaturation of antigenic sites during the transfer. Further studies are required to validate this issue. Nevertheless, although the DBM-filter technique allows visualization of immune complexes, the solid-phase RIA appears to be necessary for absolute quantitation of the interaction of antibodies with the polymerase polypeptides. Inhibition of RNA Polymerase I Activity. IgGs from the patients' sera were tested for their ability to inhibit the activity of RNA polymerase I from the rat hepatoma or from a human neuroblastoma. Relative to IgG from a healthy individual, increasing quantities of IgG from a MCTD patient (. S.) resulted in a progressive decrease in the activity of the rat enzyme (Fig.  3) . IgGs from MCTD, SLE, and RA patients who gave positive results in the RIA (Fig. 1) were capable of inhibiting the enzyme Effect of immunoglobulins from a MCTD patient on RNA polymerase I activity. Purified rat hepatoma RNA polymerase I was assayed as described (17) in the presence of 1.0 mg of total IgG containing increasing quantities of IgG from MCTD patient I.S. and decreasing quantities of IgG from a healthy control subject. IgG fractions were prepared as outlined (17) . Results are the mean of triplicate samples and are expressed as percent of the control reaction containing only IgG from the healthy subject; 100% activity corresponds to 3.4 ± 0.2 pmol (mean ± SEM; 80 cpm/pmol) of [3H]UMP incorporated into RNA in 30 min at 30°0. from both sources ( Table 2 ). The human enzyme was inhibited to a lesser extent than the rat enzyme. This was most likely due to the use ofa partially purified human polymerase preparation. Because IgG from a RA patient (T. F.) who did not have anti-RNA polymerase I antibodies had no effect on polymerase I activity (Table 2 ), the ability of the patients' IgGs to inhibit RNA synthesis was clearly related to the relative concentration of anti-RNA polymerase I antibodies. These results thus confirmed the validity of the RIA and DBM-filter techniques in the detection of anti-RNA polymerase I antibodies and further demonstrated that the rat enzyme was an appropriate test antigen for the human antibodies. DISCUSSION Numerous reports have described the presence of antibodies directed against a variety of cellular components in sera from individuals with rheumatic diseases (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . However, in this investigation we describe the presence of antibodies against T.F.
Purified rat RNA polymerase I or RNA polymerase I that had been extracted from isolated nuclei (14) of a human neuroblastoma and partially purified by chromatography on a DEAE-Sephadex column (14) was assayed, as described in the legend to Fig. 3, in (17) and that the kinase may have a role in regulating ribosomal gene transcription (16 
